alglucosidase alfa
A Phase 3/4 Prospective Study to Characterize the Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT01410890/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза IV — препарат уже зарегистрирован. Собирают дополнительные сведения о пользе и безопасности при обычном применении.
- Исследование завершено, новых участников не набирают.
- Возраст участников: любой. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 21 чел. во всех странах исследования.
- Плановая дата окончания (11.2020) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 6 · невключение: 4
Критерии включения
- A participant was to meet all of the following criteria to be eligible for this study:
- The participant and/or the participant's parent/legal guardian was willing and able to provide signed informed consent.
- The participant had a confirmed acid alpha-glucosidase (GAA) enzyme deficiency from skin, blood, or muscle tissue and/or 2 confirmed GAA gene mutations.
- Infant and toddler Pompe disease participants could be included in the study only under condition (minimal body weight) that the trial-related blood loss (including any losses in the maneuver) would not exceed 3 percent (%) of the total blood volume during a period of 4 weeks and would not exceed 1 % at any single time.
- The participant, if female and of childbearing potential, must have had a negative pregnancy test (urine beta-human chorionic gonadotropin) at screening. Note: All female participants of childbearing potential and sexually mature males must have agreed to use a medically accepted method of contraception throughout the study.
- For participants previously treated with alglucosidase alfa the participant had received alglucosidase alfa for at least 6 months.
Критерии невключения
- A participant who met any of the following criteria was excluded from this study:
- The participant was participating in another clinical study using an investigational product.
- The participant, in the opinion of the Investigator, was unable to adhere to the requirements of the study.
- The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Источник: ClinicalTrials.gov, NCT01410890 · запись обновлена в реестре 28 марта 2022.
Дизайн и результаты
Что измеряют — первичные конечные точки (7), вторичных — 7
- Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Alglucosidase Alfa — Pre-dose and at 1, 2, 4, 8, 12, and 24 hours Post-dose on Day 1
- Pharmacokinetics: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Alglucosidase Alfa — Pre-dose and at 1, 2, 4, 8, 12, and 24 hours Post-dose on Day 1
- Pharmacokinetics: Area Under the Plasma Concentration-Time Curve (AUC) of Alglucosidase Alfa — Pre-dose and at 1, 2, 4, 8, 12, and 24 hours Post-dose on Day 1
- Pharmacokinetics: Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Alglucosidase Alfa — Pre-dose and at 1, 2, 4, 8, 12, and 24 hours Post-dose on Day 1
- Pharmacokinetics: Terminal Elimination Half-life (T1/2) of Alglucosidase Alfa — Pre-dose and at 1, 2, 4, 8, 12, and 24 hours Post-dose on Day 1
- Pharmacokinetics: Total Systemic Clearance (CL) of Alglucosidase Alfa — Pre-dose and at 1, 2, 4, 8, 12, and 24 hours Post-dose on Day 1
- Pharmacokinetics: Volume of Distribution at Steady State (Vss) of Alglucosidase Alfa — Pre-dose and at 1, 2, 4, 8, 12, and 24 hours Post-dose on Day 1
Цель исследования
* The primary objective of this study was to characterize the pharmacokinetics (PK) of alglucosidase alfa manufactured at the 4000 L scale in participants who had a confirmed diagnosis of Pompe disease.
* A secondary objective of this study was to evaluate and explore the relationship between anti-recombinant human acid alpha-glucosidase antibody titers and the PK of alglucosidase alfa.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT01410890 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.